Core Viewpoint - The announcement of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog, highlights the inclusion of several new drugs from various pharmaceutical companies, indicating potential growth opportunities in the healthcare sector [1][5]. Group 1: New Drug Inclusions - Green Leaf Pharmaceutical has five new products included in the 2025 National Medical Insurance Drug Catalog or the Commercial Health Insurance Innovative Drug Catalog, including MiMeiXin and RuiBaiLai, marking significant advancements in pain management and treatment options [2][6]. - RoXin Pharmaceutical's core innovative drug, TaiXinZan, has been included in the 2025 National Medical Insurance Drug Catalog, achieving full coverage for its approved indications [6][7]. - Dongcheng Pharmaceutical's product, Technetium-99m labeled Tetrakis, has been successfully included in the National Medical Insurance Drug Catalog, filling a gap in the market for myocardial perfusion imaging agents [8][9]. Group 2: Stock Performance - As of December 8, Green Leaf Pharmaceutical's stock price reached 3.05 yuan, reflecting a 40.55% increase since the beginning of the year [2][6]. - RoXin Pharmaceutical's stock price was 5.18 yuan as of December 9, showing a 35.6% increase year-to-date [7][8]. - Dongcheng Pharmaceutical's stock price was 14.66 yuan as of December 9, with a year-to-date increase of 20.26% [8][9]. - Rongchang Bio's stock price reached 85.29 yuan as of December 9, marking a significant increase of 183.25% since the start of the year [9]. Group 3: Innovative Treatments - MiMeiXin is noted as the first oral naloxone formulation in China for pain management, while RuiBaiLai offers a unique long-acting injection regimen [2][6]. - TaiXinZan has demonstrated superior efficacy in eradicating Helicobacter pylori compared to traditional treatments, showcasing its innovative therapeutic mechanism [7]. - HaiPuYi, a product from LuNan Pharmaceutical, has been included in the first edition of the Commercial Health Insurance Innovative Drug Catalog, addressing a critical shortage in the treatment of phenylketonuria [9].

Group 1 - The core point of the article is that Dongcheng Pharmaceutical has received approval for a new specification of its low molecular weight heparin product, dalteparin sodium injection, from the National Medical Products Administration [1] - The newly approved specification is 0.2ml: 5000AXaIU, which expands the product's market offerings [1] - Dalteparin sodium injection is primarily used for the treatment of acute deep vein thrombosis, highlighting its significance in the therapeutic area of anticoagulation [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a new specification (0.2ml: 5000AXaIU) for its low molecular weight heparin product, Daltaparin Sodium Injection [1] Group 1 - The newly approved specification for Daltaparin Sodium Injection is aimed at enhancing the product's market offerings [1] - Daltaparin Sodium Injection is primarily used for the treatment of acute deep vein thrombosis and for preventing thrombus formation during hemodialysis and blood filtration in patients with acute or chronic renal failure [1] - The product also addresses unstable coronary artery diseases, including unstable angina and non-Q wave myocardial infarction, as well as preventing surgery-related thrombus formation [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a new specification (0.2ml: 5000AXaIU) for its low molecular heparin product, Dalteparin Sodium Injection [1] Group 1: Product Information - Dalteparin Sodium Injection is a low molecular weight heparin preparation with anticoagulant properties, primarily indicated for the treatment of acute deep vein thrombosis [1] - The product is also used to prevent acute renal failure or chronic renal insufficiency during hemodialysis and blood filtration, as well as to treat unstable coronary artery diseases such as unstable angina and non-Q wave myocardial infarction [1] - Additionally, it is indicated for the prevention of thromboembolism associated with surgical procedures [1]

东诚北方于2025年1月向国家药品监督管理局药品审评中心（CDE）递交了达 肝素钠注射液（0.2ml：5000AXaIU）增加规格补充申请，并于2025年1月26日获 得受理。2025年12月收到《药品补充申请批准通知书》，审评结论为：经审查， 本品此次申请事项符合药品注册的有关要求，同意本品如下补充申请事项：增加 0.2ml：5000AXaIU规格，核发药品批准文号。 证券代码：002675 证券简称：东诚药业 公告编号：2025-072 烟台东诚药业集团股份有限公司 关于全资子公司药品达肝素钠注射液增加规格获批上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）收到全资子公 司烟台东诚北方制药有限公司（以下简称"东诚北方"）的通知，通知其收到国 家药品监督管理局下发的《药品补充申请批准通知书》，达肝素钠注射液新增规 格（0.2ml：5000AXaIU）获批上市。相关信息如下： 2.其他相关信息 药品名称 达肝素钠注射液 剂型 注射剂 申请事项 申请在已获批上市的达肝素钠注射液，规格：0.3ml： ...

进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为1.09亿元。 东诚药业12月9日大宗交易平台出现一笔成交，成交量600.00万股，成交金额8532.00万元，大宗交易成 交价为14.22元，相对今日收盘价折价3.00%。该笔交易的买方营业部为机构专用，卖方营业部为长江证 券股份有限公司上海徐汇区天钥桥路证券营业部。 证券时报·数据宝统计显示，东诚药业今日收盘价为14.66元，下跌0.95%，日换手率为0.78%，成交额为 8592.68万元，全天主力资金净流出465.30万元，近5日该股累计下跌2.14%，近5日资金合计净流出 2044.09万元。 （文章来源：证券时报网） 据天眼查APP显示，烟台东诚药业集团股份有限公司成立于1998年12月31日，注册资本82459.5705万人 民币。（数据宝） 12月9日东诚药业大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | 600.00 | ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [36]. Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, along with the first version of the Commercial Health Insurance Innovative Drug List, was released on December 7, 2025. This adjustment includes 114 new drugs, of which 50 are classified as Class 1 innovative drugs [3]. - The newly launched Chinese Drug Price Registration System aims to facilitate the global pricing system for innovative drugs and attract high-quality foreign drugs to the Chinese market, benefiting patients [4][5]. - The innovative drug sector is expected to continue its rise, with recommendations to focus on companies with rich pipeline layouts, high-potential innovative drugs, and leading technology platforms [11]. Summary by Sections Industry Developments - The 2025 drug list adjustment marks the eighth update since the establishment of the National Medical Insurance Bureau, reflecting ongoing efforts to enhance drug accessibility and innovation in China [3]. - The Chinese Drug Price Registration System, launched on December 2, 2025, allows pharmaceutical companies to independently declare drug prices, promoting a more transparent and globalized pricing structure [4][5]. Company Highlights - Yino Pharmaceutical has rapidly emerged in the metabolic disease treatment field since its establishment in 2014, with its core product, Isupreglutide α, receiving approval as a Class 1 innovative drug and entering commercialization [7]. Investment Strategy - The report suggests focusing on companies with diverse pipelines, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group, as well as those with high-potential innovative drugs like Sanofi and Kaiyin Technology [11]. - It also highlights the importance of companies with leading technology platforms, such as Dongcheng Pharmaceutical and WuXi AppTec, as well as upstream companies benefiting from overseas expansion [11]. Market Performance - The pharmaceutical sector experienced a decline of 0.74% last week, ranking 19th among 28 industries, while the Shanghai and Shenzhen 300 Index rose by 1.28% [14][24]. - As of December 5, 2025, the pharmaceutical sector's valuation stands at 29.30 times (TTM), with a premium of 17.46% over the overall A-share market [27].

截至2025年12月8日收盘，东诚药业（002675）报收于14.8元，较前一交易日下跌0.54%，最新总市值为 122.04亿元。该股当日开盘15.08元，最高15.25元，最低14.76元，成交额达1.03亿元，换手率为0.93%。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 同日，公司发布公告称，根据国家医疗保障局、人力资源社会保障部发布的《国家基本医疗保险、生育 保险和工伤保险药品目录（2025年）》，其全资子公司南京江原安迪科正电子研究发展有限公司的锝 [99mTc]替曲膦注射液被纳入该目录，适应症为用于诊断患有或疑似冠状动脉疾病成人的心肌灌注显 像。公告指出，该产品纳入医保目录将有利于市场推广和未来销售，但因目录自2026年1月1日起执行， 暂不会对公司经营业绩构成重大影响。 《关于锝[99mTc]替曲膦注射液纳入医保目录的公告》 《关于控股子公司获得药物临床试验批准通知书的公告》 ...

Core Insights - Yantai's biopharmaceutical industry has been identified as a key sector under the "14th Five-Year Plan," focusing on extending the industrial chain, enhancing the value chain, and integrating the supply chain [1] Group 1: Industry Overview - As of now, Yantai has 212 biopharmaceutical enterprises, including 6 listed companies, 1 unicorn, and 23 gazelle companies, along with 9 national-level specialized and innovative small giant enterprises [1] - The city has introduced strategic development plans for medical isotopes and marine drugs, positioning its biopharmaceutical cluster among the first national strategic emerging industry clusters [1] Group 2: Infrastructure Development - The "Blue Pharmaceutical Valley" park has been established with a total investment of 12 billion yuan and a construction area of 1.3 million square meters, attracting 34 biopharmaceutical companies [2] - Several specialized parks are under construction, including the IVD medical device industrial park and the international biopharmaceutical valley, contributing to the growth of major enterprises [2] Group 3: Innovation and Ecosystem - Yantai is building a comprehensive vertical ecosystem for the biopharmaceutical industry, covering product R&D, results transformation, inspection and approval, and production and sales [3] - The city has established a high-level innovation system with 1 major research institute and over 100 provincial-level innovation platforms, aiming to facilitate the development of new drugs [3] Group 4: Competitive Advantage - The focus is on two cutting-edge sectors: medical isotopes and radioactive drugs, as well as cell and gene therapy, while also nurturing high-end generics and medical devices [4] - The Blue Pharmaceutical Valley is the largest domestic park with nuclear drug production qualifications, housing significant players in the nuclear medicine field [5]

Group 1: National Medical Insurance Directory Inclusion - Heng Rui Medicine has multiple drugs included in the 2025 National Medical Insurance Directory [1] - Xing Qi Eye Medicine has 39 products continuing to be included in the National Medical Insurance Drug Directory [1] - Bei Da Pharmaceutical has four products included in the National Medical Insurance Drug Directory [1] - Junshi Biosciences has added indications for Tuoyi® and included Junshida® in the National Medical Insurance Directory [1] - Zhongsheng Pharmaceutical's innovative drug Angladiwei tablets have been included in the National Medical Insurance Directory through negotiation [1] - Yiling Pharmaceutical's subsidiary has its exclusive product Qifang Nasal Tablets included in the National Medical Insurance Directory, totaling 12 exclusive patented traditional Chinese medicine products [1] - Aosaikang's product Liratinib tablets (Aoyi Xin®) has been included in the 2025 National Medical Insurance Directory [1] - Kanghong Pharmaceutical's product Kangbai Xip eye injection (Langmu) has been included in the 2025 National Medical Insurance Directory [1] - Dongcheng Pharmaceutical's Technetium-99m injection has been included in the medical insurance directory; its subsidiary has received clinical trial approval for 177Lu-LNC1009 injection [1] - Micron Biomedical's Sidabena tablets have been included in the National Medical Insurance Directory for regular Class B management [1] - Haichuang Pharmaceutical's Deuteroenzalutamide soft capsules have been included in the National Medical Insurance Directory for the first time [1] - Huadong Medicine's subsidiary products and cooperative products have been included in the National Medical Insurance and commercial insurance innovative drug directory [1] - Aidi Pharmaceutical's two anti-HIV innovative drugs continue to be included in the National Medical Insurance Directory through a simplified renewal process [1] Group 2: Corporate Developments - Hengyin Technology has signed a cooperation agreement with Muxi Co., focusing on the domestic GPU scenario [1] - Jia Jian Co. is planning a change in control, with stock resuming trading on December 8 [2] - Gu Ao Technology's actual controller is planning a change in control, leading to stock suspension [2] Group 3: Financial Performance - Tianbang Food reported a commodity pig sales revenue of 654 million yuan in November, a month-on-month increase of 7.66% [3] - Tian Ci Materials' controlling shareholder has committed not to reduce company shares [3]